Key result
Rivaroxaban therapy for 3 months resulted in near-complete dissolution of a large metastatic thymic carcinoma-associated right atrial thrombus.
Why the study?
Direct oral anticoagulants are emerging as alternatives to low molecular weight heparins to attenuate cancer-associated venous thromboembolism events.
Case Report (n=1)
No
Direct oral anticoagulation with rivaroxaban may be an effective alternative to low molecular weight heparin for the dissolution of cancer-associated right atrial thrombi.
Answers are grounded in this paper and cite their sources.
May support rivaroxaban for cancer-associated right atrial thrombi; hypothesis-generating and requires prospective confirmation.
Thymic carcinoma typically exhibits more clinically aggressive behavior and portends a worse prognosis as compared to thymoma. Venous thromboembolism is a significant cause of morbidity and mortality in oncologic patients. Traditionally, the standard-of-care management of cancer-associated venous thromboembolism has been therapeutic anticoagulation with low molecular weight heparins; however, with the advent of direct oral anticoagulants, there is an ongoing paradigm shift to transition to these novel agents in an attempt to attenuate cancer-associated venous thromboembolism events. We describe an exceedingly rare case of metastatic thymic carcinoma-associated right atrial thrombus with high-risk embolic features, which subsequently underwent near-complete dissolution with rivaroxaban after 3 months.
No takes yet. Share an insight, caveat, or question.
Nimblette et al. (2020) conducted a case report in Metastatic thymic carcinoma-associated right atrial thrombus (n=1). Rivaroxaban was evaluated on Right atrial thrombus dissolution. Rivaroxaban therapy for 3 months resulted in near-complete dissolution of a large metastatic thymic carcinoma-associated right atrial thrombus.
Synapse has enriched 10 related papers. Consider them for comparative context: